These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 694846)

  • 1. Assay of platelet factor 4(PF4) using synthetic thrombin substrates.
    Wohl H; Kujawa M; Prager L
    Thromb Res; 1978 Aug; 13(2):289-95. PubMed ID: 694846
    [No Abstract]   [Full Text] [Related]  

  • 2. Measurement of the heparin enhanced-antithrombin III/thrombin reaction rate in the presence of synthetic substrate.
    Griffith MJ
    Thromb Res; 1982 Feb; 25(3):245-53. PubMed ID: 7064134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inhibition by heparin of the intrinsic pathway activation of factor X in the absence of antithrombin-III.
    Ofosu F; Blajchman MA; Hirsh J
    Thromb Res; 1980 Nov; 20(4):391-403. PubMed ID: 6782701
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibition of esterase and amidase activities of alpha- and beta-thrombin in the presence of antithrombin III and heparin.
    Borsodi A; Machovich R
    Biochim Biophys Acta; 1979 Feb; 566(2):385-9. PubMed ID: 570423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Heparin and antiheparin in young children. 1. Report: development of a method for determining heparin and antiheparin in the antithrombin-thrombin system].
    Domula M; Weissbach G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(5):808-23. PubMed ID: 6188669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin cofactor activity measured with an amidolytic method.
    Odegard OR; Lie M; Abildgaard U
    Thromb Res; 1975 Apr; 6(4):287-94. PubMed ID: 49087
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhibition of thrombin-catalyzed reactions in blood coagulation and platelet activation by heparin fractions in the absence of antithrombin III.
    Baruch D; Lindhout T; Wagenvoord R; Hemker HC
    Haemostasis; 1986; 16(2):71-81. PubMed ID: 3086193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of heparin and low molecular weight heparins on thrombin-induced blood platelet activation in the absence of antithrombin III.
    Baruch D; Franssen J; Hemker HC; Lindhout T
    Thromb Res; 1985 Jun; 38(5):447-58. PubMed ID: 3160132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new principle in heparin assaying based on partial neutralization of heparin with polybrene.
    Talstad I
    Thromb Res; 1980 May 1-15; 18(3-4):485-91. PubMed ID: 7414543
    [No Abstract]   [Full Text] [Related]  

  • 10. Prevention of thrombin/antithrombin III reaction in the presence of protamine or polybrene.
    Oshima G
    Thromb Res; 1988 Sep; 51(6):565-74. PubMed ID: 3187966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [From heparin to synthetic antithrombotic oligosaccharides].
    Petitou M
    Bull Acad Natl Med; 2003; 187(1):47-56; discussion 56-7. PubMed ID: 14556453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic peptide substrates in hemostatic testing.
    Fareed J; Messmore HL; Walenga JM; Bermes EW
    Crit Rev Clin Lab Sci; 1983; 19(2):71-134. PubMed ID: 6373139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of factor X and prothrombin in antithrombin-III depleted plasma: the effects of heparin.
    Ofosu FA; Blajchman MA; Modi G; Cerskus AL; Hirsh J
    Thromb Res; 1981 Aug 15-Sep 1; 23(4-5):331-45. PubMed ID: 7324001
    [No Abstract]   [Full Text] [Related]  

  • 14. Binding of platelet factor 4 to heparin oligosaccharides.
    Denton J; Lane DA; Thunberg L; Slater AM; Lindahl U
    Biochem J; 1983 Feb; 209(2):455-60. PubMed ID: 6847629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin neutralizing activity (HNA) and antithrombin III in coronary artery disease.
    Cella G; Russo R
    Thromb Haemost; 1977 Oct; 38(3):696-700. PubMed ID: 579515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An improved procedure for quantitation of platelet factor 4.
    Saleem A; Fretz K
    Am J Clin Pathol; 1977 Jun; 67(6):533-6. PubMed ID: 868792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of heparin, hirudin, and a synthetic thrombin inhibitor on antithrombin III in thrombin-induced disseminated intravascular coagulation in rats.
    Hauptmann J; Brüggener E; Markwardt F
    Haemostasis; 1987; 17(6):321-8. PubMed ID: 3428717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic substrate assays of the coagulation enzymes and their inhibitors. Comparison with clotting and immunologic methods for clinical and experimental usage.
    Messmore HL; Fareed J; Kniffin J; Squillaci G; Walenga J
    Ann N Y Acad Sci; 1981; 370():785-97. PubMed ID: 7023331
    [No Abstract]   [Full Text] [Related]  

  • 19. Platelet factor four and protamine sulfate neutralization of heparin fractionated according to anionic charge density.
    Poon MC; Hurst RE; Rives MS
    Thromb Haemost; 1982 Apr; 47(2):162-5. PubMed ID: 7101237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass.
    Mochizuki T; Olson PJ; Szlam F; Ramsay JG; Levy JH
    Anesth Analg; 1998 Oct; 87(4):781-5. PubMed ID: 9768770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.